ALX ONCOLOGY HOLDINGS INC

Clinical-stage firm developing CD47 inhibitors for hematologic and solid tumors.

ALXO | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 323 ALLERTON AVENUE, 94080 SOUTH SAN FRANCISCO
Website:: https://alxoncology.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on developing therapies that harness the immune system to combat cancer. The company's lead therapeutic candidate, evorpacept, is a next-generation CD47 checkpoint inhibitor designed to block a key signal that cancer cells use to evade immune detection. ALX Oncology is advancing evorpacept in multiple clinical trials as a potential cornerstone therapy for use in combination with other anti-cancer agents. The company's development pipeline targets a broad range of hematologic malignancies and solid tumors, with the goal of improving upon current and future standards of care for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALX ONCOLOGY HOLDINGS INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALX ONCOLOGY HOLDINGS INC

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ALX ONCOLOGY HOLDINGS INC via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

	Company	Country	Ticker
	Alpha Cognition Inc. Develops and commercializes novel treatments for neurodegenerative diseases like Alzheimer's and ALS.	United States of America	ACOG
	Alteogen Inc. Biotech firm developing next-gen ADCs and biobetters with proprietary platform technologies.	South Korea	196170
	ALTERITY THERAPEUTICS LTD Developing therapies for Parkinsonian disorders and MSA by inhibiting protein aggregation.	United States of America	ATHE
	Alto Neuroscience, Inc. Developing precision medicines for depression and schizophrenia using a brain biomarker platform.	United States of America	ANRO
	ALUMIS INC. Develops targeted oral therapies for immune-mediated diseases using precision immunology.	United States of America	ALMS
	Alvotech Develops and manufactures affordable biosimilar medicines for patients worldwide.	United States of America	ALVO
	Alvotech Holdings S.A Develops and manufactures affordable biosimilar medicines for global patient access.	Luxembourg	ALVO
	Alzamend Neuro, Inc. Developing lithium & vaccine therapies for neurodegenerative & psychiatric disorders.	United States of America	ALZN
	Alzinova AB Developing targeted immunotherapies, including a vaccine, for Alzheimer's disease.	Sweden	ALZ
$AMARIN CORP PLC\UK Logo$	AMARIN CORP PLC\UK Develops prescription therapies like Vascepa® to reduce cardiovascular risk for patients.	United States of America	AMRN